4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds and their therapeutic use

A compound of the following formula:

• or a pharmaceutically acceptable salt thereof;
• wherein:
• —R7 is a fused bicyclic C8-10heteroaryl group having exactly 1, 2, or 3 ring heteroatoms, wherein each ring heteroatom is N, S, or O;
• and wherein —R7 is:
• optionally substituted on carbon with one or more groups —RSC;
• and
• optionally substituted on secondary nitrogen, if present, with a group —RSN;
• wherein:
• each —RSC is independently:
• —RTT,
• —F, —Cl, —Br, —I,
• —OH, —ORTT,
• -LT-OH, -LT-ORTT,
• —CF3, —CHF2, —OCF3, —OCHF2,
• —NH2, —NHRTT, —NRTT2, —RTM,
• -LT-NH2, -LT-NHRTT, -LT-NRTT2, -LT-RTM,
• —C(═O)OH, —C(═O)ORTT,
• —OC(═O)RTT,
• —C(═O)NH2, —C(═O)NHRTT, —C(═O)NRTT2, —C(═O)RTM,
• —NHC(═O)RTT, —NRTNC(═O)RTT,
• —NHC(═O)NH2, —NHC(═O)NHRTT, —NHC(═O)NRTT2, —NHC(═O)RTM,
• —NRTNC(═O)NH2, —NRTNC(═O)NHRTT, —NRTNC(═O)NRTT2, —NRTNC(═O)RTM,
• —NHC(═O)ORTT, —NRTNC(═O)ORTT,
• —OC(═O)NH2, —OC(═O)NHRTT, —OC(═O)NRTT2, —OC(═O)RTM,
• —C(═O)RTT,
• —SRTT, —S(═O)RTT, —S(═O)2RTT,
• —S(═O)NH2, —S(═O)NHRTT, —S(═O)NRTT2, —S(═O)RTM,
• —S(═O)2NH2, —S(═O)2NHRTT, —S(═O)2NRTT2, —S(═O)2RTM,
• —NHS(═O)2RTT, —NRTNS(═O)2RTT,
• —CN, or —NO2;
• each —RSN is independently:
• —RTT,
• -LT-OH, -LT-ORTT,
• -LT-NH2, -LT-NHRTT, -LT-NRTT2, -LT-RTM,
• —C(═O)RTT,
• —C(═O)ORTT,
• —C(═O)NH2, —C(═O)NHRTT, —C(═O)NRTT2, —C(═O)RTM, or
• —S(═O)2RTT;
• wherein:
• each -LT- is independently linear or branched saturated C1-4alkylene;
• each —RTT is independently —RTT, —RTT2, -LTT-RTT2, —RTT3, or -LTT-RTT3;
• each —RTT1 is independently linear or branched saturated C1-6alkyl, and is optionally substituted with one or more groups selected from —F, —OH, and —ORTTT;
• each —RTT2 is saturated C3-6cycloalkyl, and is optionally substituted with one or more groups selected from —F, —RTTT, —OH, and —ORTTT;
• each —RTT3 is independently phenyl or naphthyl, and is optionally substituted with one or more groups selected from —F, —Cl, —Br, —I, —RTTT, OH, —ORTTT, —OCF3, —NH2, —NHRTTT, and —NRTTT2;
• each -LTT- is independently linear or branched saturated C1-4alkylene;
• each —RTN is linear or branched saturated C1-4alkyl, phenyl, or benzyl;
• each —RTM is independently azetidino, pyrrolidino, piperidino, piperazino, morpholino, azepano, or diazepano, and is:
• optionally substituted on carbon with one or more groups selected from:
• —RTMM, —C(═O)RTMM, —S(═O)2RTMM, —F, —NH2, —NHRTMM, —NRTMM2, —OH, and —ORTMM;
• and
• optionally substituted on secondary nitrogen, if present, with a group selected from:
• —RTMM, —C(═O)RTMM, —C(═O)ORTMM, and —S(═O)2RTMM;
• each —RTTT is independently linear or branched saturated C1-4alkyl, phenyl, or benzyl;
• and
• each —RTMM is independently linear or branched saturated C1-4alkyl, phenyl, or benzyl;
• and wherein:
• -L7- is independently linear or branched saturated C1-3alkylene, and is optionally substituted with one or more groups selected from —F, —OH, and —OMe;
• —R3 is independently —R3A or —R3B;
• —R3A is independently linear or branched saturated C1-6alkyl, and is optionally substituted with one or more groups selected from —F, —OH, and —OMe;
• and
• —R3B is independently saturated C3-7cycloalkyl, and is optionally substituted with one or more groups selected from —F, —OH, and —OMe.